These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30526333)

  • 41. Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro.
    Im Hof M; Williamson L; Summerfield A; Balmer V; Dutoit V; Kandimalla ER; Yu D; Zurbriggen A; Doherr MG; Peel J; Roosje PJ
    Vet Immunol Immunopathol; 2008 Jul; 124(1-2):120-31. PubMed ID: 18452997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemical etiology of nucleic acid structure: the alpha-threofuranosyl-(3'-->2') oligonucleotide system.
    Schöning K; Scholz P; Guntha S; Wu X; Krishnamurthy R; Eschenmoser A
    Science; 2000 Nov; 290(5495):1347-51. PubMed ID: 11082060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines.
    Assaf A; Esteves H; Curnow SJ; Browning MJ
    Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Darwinian evolution of an alternative genetic system provides support for TNA as an RNA progenitor.
    Yu H; Zhang S; Chaput JC
    Nat Chem; 2012 Jan; 4(3):183-7. PubMed ID: 22354431
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological applications of xeno nucleic acids.
    Morihiro K; Kasahara Y; Obika S
    Mol Biosyst; 2017 Jan; 13(2):235-245. PubMed ID: 27827481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TLR9 activation is defective in common variable immune deficiency.
    Cunningham-Rundles C; Radigan L; Knight AK; Zhang L; Bauer L; Nakazawa A
    J Immunol; 2006 Feb; 176(3):1978-87. PubMed ID: 16424230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
    Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
    Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthetic α-l-Threose Nucleic Acids Targeting BcL-2 Show Gene Silencing and in Vivo Antitumor Activity for Cancer Therapy.
    Wang F; Liu LS; Lau CH; Han Chang TJ; Tam DY; Leung HM; Tin C; Lo PK
    ACS Appl Mater Interfaces; 2019 Oct; 11(42):38510-38518. PubMed ID: 31556592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional Comparison of Laboratory-Evolved XNA Polymerases for Synthetic Biology.
    Medina E; Yik EJ; Herdewijn P; Chaput JC
    ACS Synth Biol; 2021 Jun; 10(6):1429-1437. PubMed ID: 34029459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Origin of life. A simpler nucleic acid.
    Orgel L
    Science; 2000 Nov; 290(5495):1306-7. PubMed ID: 11185405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.
    Scholtzova H; Do E; Dhakal S; Sun Y; Liu S; Mehta PD; Wisniewski T
    J Neurosci; 2017 Jan; 37(4):936-959. PubMed ID: 28123027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
    Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
    Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis of 2'-Deoxy-α-l-threofuranosyl Nucleoside Triphosphates.
    Bala S; Liao JY; Zhang L; Tran CN; Chim N; Chaput JC
    J Org Chem; 2018 Aug; 83(16):8840-8850. PubMed ID: 30011988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cathepsins are required for Toll-like receptor 9 responses.
    Matsumoto F; Saitoh S; Fukui R; Kobayashi T; Tanimura N; Konno K; Kusumoto Y; Akashi-Takamura S; Miyake K
    Biochem Biophys Res Commun; 2008 Mar; 367(3):693-9. PubMed ID: 18166152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
    Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
    J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation and regulation of toll-like receptor 9: CpGs and beyond.
    Kindrachuk J; Potter J; Wilson HL; Griebel P; Babiuk LA; Napper S
    Mini Rev Med Chem; 2008 Jun; 8(6):590-600. PubMed ID: 18537714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct role of MAPKAPK-2 in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands.
    Thuraisingam T; Xu YZ; Moisan J; Lachance C; Garnon J; Di Marco S; Gaestel M; Radzioch D
    Mol Immunol; 2007 Jul; 44(14):3482-91. PubMed ID: 17485113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
    Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
    Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.